Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 7/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31312891 | 1.00 | CASP6 (0.53) | CASP6ALDH1A1MAPTMEN1POLB | |
| SCHEMBL12068355 | 0.78 | CASP6 (0.54) | CASP6ALDH1A1MAPTMEN1POLB | |
| SCHEMBL12069883 | 0.78 | CASP6 (0.54) | CASP6ALDH1A1MAPTMEN1POLB | |
| SCHEMBL3758295 | 0.76 | ALDH1A1 (0.59) | CASP6ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL30319339 | 0.76 | ALDH1A1 (0.59) | CASP6ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL18606165 | 0.69 | CA3 (0.35) | CASP6 | |
| SCHEMBL13527427 | 0.69 | ALDH1A1 (0.38) | CASP6ALDH1A1PLK4MAPK9LIMK1 | |
| SCHEMBL29947824 | 0.69 | GRIN2D (0.43) | CASP6ALDH1A1DAO | |
| SCHEMBL31287982 | 0.66 | ALDH1A1 (0.37) | CASP6ALDH1A1MAPTPOLBPARP1 | |
| SCHEMBL25362170 | 0.65 | DAO (0.48) | ALDH1A1DAOLIMK1CLK4ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154130-A1 | NOVEL THR BETA ANALOGS AND USES THEREOF | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2025-05-15 | — | — | US | disclosed |
| WO-2023154842-A1 | THR BETA ANALOGS AND USES THEREOF | MADRIGAL PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154842-A1 | THR BETA ANALOGS AND USES THEREOF | MADRIGAL PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-9242961-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-1984353-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2418209-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2418209-A1 | Aurora kinase modulators and method of use | Amgen Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-8022221-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7560551-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1984353-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, AURKB | CASP6 2898/4885ALDH1A1 2864/4885MAPT 2283/4885 |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | CASP6 3592/4885ALDH1A1 1645/4885MAPT 1958/4885 |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, AURKB | CASP6 2898/4885ALDH1A1 2864/4885MAPT 2283/4885 |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, AURKB | CASP6 2898/4885ALDH1A1 2864/4885MAPT 2283/4885 |
| US-20250154130-A1 | NOVEL THR BETA ANALOGS AND USES THEREOF | THRB, THRA, TSHR | CASP6 3504/4885ALDH1A1 2389/4885MAPT 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.